Showing 41 - 60 results of 148 for search '"Hematopoietic stem cell transplantation"', query time: 0.07s Refine Results
  1. 41
  2. 42
  3. 43
  4. 44
  5. 45

    Increased Co-Expression of PD-L1 and CTLA-4 Predicts Poor Overall Survival in Patients with Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation by Chen C, Qiu K, Chen J, Wang S, Zhang Y, Wang C, Li Y

    Published 2025-01-01
    “…This study aims to investigate the significance of the alteration of IC co-expression for evaluating the prognosis of AML patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT).Patients and Methods: Quantitative real-time PCR (qRT-PCR) data of bone marrow (BM) samples from 62 de novo AML patients, including 37 patients who received allo-HSCT and 25 patients who received chemotherapy only, were used for prognostic analysis.Results: High expression of PD-1, PD-L1, PD-L2, CTLA-4, and LAG-3 was associated with poor overall survival (OS) in AML patients receiving allo-HSCT, while the expression levels of PD-1, PD-L2, CTLA-4, and LAG-3, other than PD-L1, were not significantly correlated with OS in AML patients receiving chemotherapy. …”
    Get full text
    Article
  6. 46

    The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation by Xiaoping Li, Yu Li, Dingsong Zhang, Xiaozhuang Hu, Lin Liu, Zhongtao Yuan, Shiqi Li, Yancheng Dong, Yingnian Chen, Sanbin Wang

    Published 2025-01-01
    “…Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. …”
    Get full text
    Article
  7. 47
  8. 48

    Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma by Jiaying Wu, Wanying Liu, Yang Cao, Yang Yang, Zhen Shang, Mi Zhou, Yicheng Zhang, Fankai Meng, Xiaojian Zhu, Yi Xiao

    Published 2024-11-01
    “…Abstract Background Several reports have indicated that chimeric antigen receptor (CAR) T-cell therapy following autologous hematopoietic stem cell transplantation (ASCT) is a promising strategy for refractory/relapsed (r/r) central nervous system lymphoma (CNSL), but the number of reported cases is limited. …”
    Get full text
    Article
  9. 49

    Refractory human cytomegalovirus infection without evidence of genetic resistance in the UL-54 and UL-97 genes in a pediatric hematopoietic stem cell transplant recipient: a case report by Alejandra Pando-Caciano, Ketty Adid Escudero-Ramirez, Jackeline Carol Rodríguez-Torres, Holger Maita-Malpartida, Holger Maita-Malpartida

    Published 2024-02-01
    “…Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (HSCT). Management of refractory CMV infections, especially in developing countries, can be challenging due to the limited availability of second and third-line antiviral drugs or alternative treatments. …”
    Get full text
    Article
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60